Lexicon Pharmaceuticals’ (LXRX) “Buy” Rating Reaffirmed at HC Wainwright

Lexicon Pharmaceuticals (NASDAQ:LXRX)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research report issued to clients and investors on Tuesday, Benzinga reports. They presently have a $10.00 target price on the biopharmaceutical company’s stock.

Separately, StockNews.com upgraded Lexicon Pharmaceuticals to a “sell” rating in a research note on Tuesday, July 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $7.50.

Lexicon Pharmaceuticals Stock Up 1.2 %

LXRX stock opened at $1.63 on Tuesday. The firm has a 50-day moving average price of $1.83 and a 200-day moving average price of $1.94. Lexicon Pharmaceuticals has a 12 month low of $0.92 and a 12 month high of $3.73. The company has a current ratio of 11.51, a quick ratio of 11.49 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $401.37 million, a P/E ratio of -1.96 and a beta of 1.35.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.01. Lexicon Pharmaceuticals had a negative net margin of 5,509.34% and a negative return on equity of 105.38%. The business had revenue of $1.65 million during the quarter, compared to the consensus estimate of $2.74 million. During the same quarter in the prior year, the firm earned ($0.22) EPS. As a group, equities research analysts anticipate that Lexicon Pharmaceuticals will post -0.69 EPS for the current fiscal year.

Hedge Funds Weigh In On Lexicon Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Victory Capital Management Inc. grew its stake in shares of Lexicon Pharmaceuticals by 22.0% in the fourth quarter. Victory Capital Management Inc. now owns 32,187 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 5,813 shares during the last quarter. Principal Securities Inc. acquired a new position in Lexicon Pharmaceuticals during the 4th quarter worth about $33,000. RPO LLC bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $49,000. Cantor Fitzgerald L. P. bought a new stake in shares of Lexicon Pharmaceuticals in the 4th quarter valued at about $25,000. Finally, BVF Inc. IL increased its stake in shares of Lexicon Pharmaceuticals by 22.2% in the fourth quarter. BVF Inc. IL now owns 24,435,632 shares of the biopharmaceutical company’s stock valued at $37,387,000 after buying an additional 4,440,300 shares during the period. 74.70% of the stock is currently owned by institutional investors and hedge funds.

Lexicon Pharmaceuticals Company Profile

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.